{"id":"https://openalex.org/W2523965286","doi":"https://doi.org/10.1200/jco.2010.28.15_suppl.2022","title":"Can OS-6 replace PFS-6 as a primary endpoint in phase II studies on glioblastoma patients given antiangiogenetic drugs?","display_name":"Can OS-6 replace PFS-6 as a primary endpoint in phase II studies on glioblastoma patients given antiangiogenetic drugs?","publication_year":2010,"publication_date":"2010-05-20","ids":{"openalex":"https://openalex.org/W2523965286","doi":"https://doi.org/10.1200/jco.2010.28.15_suppl.2022","mag":"2523965286"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2010.28.15_suppl.2022","doi":"https://doi.org/10.1200/jco.2010.28.15_suppl.2022","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2010.28.15_suppl.2022","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5063327760","display_name":"Enrico Franceschi","orcid":"https://orcid.org/0000-0001-9332-4677","observed_orcids":["https://orcid.org/0000-0001-9332-4677"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"E. Franceschi","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087336206","display_name":"Alba Ariela Brandes","orcid":"https://orcid.org/0000-0002-2503-9089","observed_orcids":["https://orcid.org/0000-0002-2503-9089"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"A. A. Brandes","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5019091770","display_name":"A. Tosoni","orcid":"https://orcid.org/0000-0001-9004-2623","observed_orcids":["https://orcid.org/0000-0001-9004-2623"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"A. Tosoni","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040507024","display_name":"A. Bacci","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"A. Bacci","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035607472","display_name":"Luca Morandi","orcid":"https://orcid.org/0000-0002-3810-9760","observed_orcids":["https://orcid.org/0000-0002-3810-9760"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"L. Morandi","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088925857","display_name":"Federica Spagnolli","orcid":"https://orcid.org/0000-0002-3703-3717","observed_orcids":["https://orcid.org/0000-0002-3703-3717"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"F. Spagnolli","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046330547","display_name":"Roberta Degli Esposti","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"R. Degli Esposti","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034431443","display_name":"Stefania Bartolini","orcid":"https://orcid.org/0000-0003-1255-0109","observed_orcids":["https://orcid.org/0000-0003-1255-0109"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"S. Bartolini","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013207477","display_name":"Rosalba Poggi","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"R. Poggi","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5041540581","display_name":"M. Ermani","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M. Ermani","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":4,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"28","issue":"15_suppl","first_page":"2022","last_page":"2022"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10129","display_name":"Glioma Diagnosis and Treatment","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10129","display_name":"Glioma Diagnosis and Treatment","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11235","display_name":"Statistical Methods in Clinical Trials","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2613","display_name":"Statistics and Probability"},"field":{"id":"https://openalex.org/fields/26","display_name":"Mathematics"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T10422","display_name":"Angiogenesis and VEGF in Cancer","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/recurrent-glioblastoma","display_name":"recurrent glioblastoma","score":0.9129999876022339},{"id":"https://openalex.org/keywords/primary-endpoint","display_name":"primary endpoint","score":0.6340000033378601},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.7620000243186951},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.953000009059906},{"id":"https://openalex.org/keywords/angiogenesis-inhibitors","display_name":"angiogenesis inhibitors","score":0.7990000247955322},{"id":"https://openalex.org/keywords/temozolomide","display_name":"temozolomide","score":0.8320000171661377},{"id":"https://openalex.org/keywords/nitrosourea-chemotherapy","display_name":"nitrosourea chemotherapy","score":0.7649999856948853},{"id":"https://openalex.org/keywords/second-line-treatment","display_name":"second-line therapy","score":0.7829999923706055},{"id":"https://openalex.org/keywords/mgmt-promoter-methylation","display_name":"MGMT promoter methylation","score":0.7540000081062317},{"id":"https://openalex.org/keywords/blood-brain-barrier","display_name":"blood-brain barrier","score":0.6399999856948853},{"id":"https://openalex.org/keywords/prognostic-factors","display_name":"prognostic factors","score":0.7450000047683716},{"id":"https://openalex.org/keywords/contrast-enhancement","display_name":"contrast enhancement","score":0.35899999737739563},{"id":"https://openalex.org/keywords/tumor-burden-assessment","display_name":"tumor burden assessment","score":0.5770000219345093}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9032801389694214},{"id":"https://openalex.org/C2777389519","wikidata":"https://www.wikidata.org/wiki/Q425088","display_name":"Temozolomide","level":3,"score":0.860312819480896},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.7487014532089233},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6916793584823608},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.6177592277526855},{"id":"https://openalex.org/C2780739268","wikidata":"https://www.wikidata.org/wiki/Q2112244","display_name":"Progression-free survival","level":3,"score":0.5308189392089844},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.4585840702056885},{"id":"https://openalex.org/C2776194525","wikidata":"https://www.wikidata.org/wiki/Q282142","display_name":"Glioblastoma","level":2,"score":0.4279642105102539},{"id":"https://openalex.org/C141341695","wikidata":"https://www.wikidata.org/wiki/Q2368661","display_name":"Surrogate endpoint","level":2,"score":0.42705273628234863},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.4140101373195648},{"id":"https://openalex.org/C66339696","wikidata":"https://www.wikidata.org/wiki/Q6089397","display_name":"Log-rank test","level":3,"score":0.41372373700141907},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.3719908595085144},{"id":"https://openalex.org/C50382708","wikidata":"https://www.wikidata.org/wiki/Q223218","display_name":"Proportional hazards model","level":2,"score":0.3716273605823517},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.36368948221206665},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.08367946743965149}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2010.28.15_suppl.2022","doi":"https://doi.org/10.1200/jco.2010.28.15_suppl.2022","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2010.28.15_suppl.2022","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.98580002784729,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W1999340762","https://openalex.org/W2137832651","https://openalex.org/W2590149086","https://openalex.org/W2162459663","https://openalex.org/W2589232444","https://openalex.org/W2129948415","https://openalex.org/W2081013010","https://openalex.org/W2153384261","https://openalex.org/W2313882001","https://openalex.org/W2026506846"],"abstract_inverted_index":{"2022":[0],"Background:":[1],"In":[2,258],"the":[3,16,37,47,71,80,87,108,167,170,174,234,259,266,277,280,292,295,322],"last":[4],"decade,":[5],"progression-free":[6],"survival":[7,51],"(PFS)":[8],"at":[9,119,155],"6":[10],"months":[11,241,250],"(PFS-6)":[12],"has":[13],"been":[14],"considered":[15,321,341],"best":[17],"endpoint":[18,96],"in":[19,86,200,205,291,297,310,328],"phase":[20,39,98,329],"II":[21,99,330],"trials":[22],"on":[23,46,67,130,332],"recurrent":[24,333],"glioblastoma":[25],"(GBM).":[26],"However,":[27],"since":[28],"a":[29,93,128,304,315,343],"new":[30],"standard":[31],"of":[32,83,92,107,151,169,207,236,279,317],"care":[33],"was":[34,110,125,163,203,211,239,270],"established":[35],"by":[36,69],"EORTC/NCIC":[38],"III":[40],"trial,":[41],"no":[42],"data":[43,66],"have":[44],"reported":[45],"PFS-6":[48,244,316],"or":[49,349,353],"overall":[50],"(OS)":[52],"obtained":[53],"with":[54,265,272],"second":[55,116,267,281,305],"line":[56,117,268,282,306],"treatment":[57,118,154,269,283,307],"following":[58],"combined":[59],"RT/TMZ.":[60,159],"Moreover,":[61],"antiangiogenic":[62,336],"agents":[63],"might":[64],"alter":[65],"response":[68],"repairing":[70],"blood-brain":[72],"barrier":[73],"and":[74,139,173,183,227,253],"diminishing":[75],"contrast":[76],"enhancement,":[77],"thus":[78],"precluding":[79],"accurate":[81],"assessment":[82],"any":[84,179],"reduction":[85],"tumor":[88],"burden.":[89],"The":[90,105,160,288],"issue":[91],"robust":[94],"primary":[95],"for":[97,115,303,324],"studies":[100,331],"is":[101],"therefore":[102],"still":[103],"open.":[104],"aim":[106],"study":[109],"to":[111,165,177,299],"evaluate":[112,166,300],"outcome":[113,301],"endpoints":[114,302],"recurrence.":[120],"Methods:":[121],"A":[122],"retrospective":[123],"analysis":[124],"made":[126,290],"using":[127],"database":[129],"653":[131],"GBM":[132,311],"patients":[133],"(pts)":[134],"followed":[135],"prospectively":[136],"between":[137,181],"5/2001":[138],"8/2008.":[140],"Eligibility":[141],"criteria:":[142],"age":[143],"\u2265":[144],"18":[145,228],"years;":[146],"PS":[147],"0-2;":[148],"histological":[149],"diagnosis":[150],"GBM;":[152],"cytotoxic":[153,326],"disease":[156,215],"progression":[157],"after":[158,308],"log-rank":[161],"test":[162],"used":[164],"significance":[168],"prognostic":[171],"variables,":[172],"Cox":[175,260],"model":[176],"ascertain":[178],"association":[180],"PFS":[182,264],"OS.":[184],"Results:":[185],"150":[186],"pts":[187,218,223,229],"(median":[188],"age:":[189],"52":[190],"years,":[191],"[24\u201376":[192],"y])":[193],"were":[194],"enrolled.":[195],"MGMT":[196],"methylation":[197],"status,":[198],"evaluable":[199],"110":[201],"pts,":[202,312],"present":[204,293],"38%":[206],"cases.":[208],"Median":[209],"OS":[210,273],"18.5":[212],"months.":[213],"At":[214,233],"progression,":[216],"40":[217],"(27%)":[219],"received":[220],"temozolomide,":[221],"92":[222],"(61%),":[224],"nitrosourea-based":[225],"chemotherapy,":[226],"(12%)":[230],"other":[231],"treatments.":[232],"time":[235],"recurrence,":[237],"mPFS":[238],"2.5":[240],"(95%CI:":[242,246,251,256],"2.0\u20133.1),":[243],"15%":[245,318],"9.5%\u201321.3%,":[247],"mOS":[248],"7.6":[249],"6.9\u20138.3)":[252],"OS-6":[254,338],"64%":[255],"56.6%\u201372.2%).":[257],"proportional":[261],"hazard":[262],"model,":[263],"correlated":[271],"measured":[274],"as":[275,342],"from":[276],"start":[278],"(p":[284],"<":[285],"0.0001).":[286],"Conclusions:":[287],"findings":[289],"study,":[294],"first":[296],"literature":[298],"RT/TMZ":[309],"confirm":[313],"that":[314],"should":[319],"be":[320,340],"cut-off":[323],"active":[325],"drugs":[327],"GBM.":[334],"For":[335],"compounds,":[337],"can":[339],"sound":[344],"endpoint.":[345],"Author":[346],"Disclosure":[347],"Employment":[348],"Leadership":[350],"Position":[351],"Consultant":[352],"Advisory":[354],"Role":[355],"Stock":[356],"Ownership":[357],"Honoraria":[358],"Research":[359],"Funding":[360],"Expert":[361],"Testimony":[362],"Other":[363],"Remuneration":[364],"Bristol-Myers":[365],"Squibb,":[366],"OncoMethylome":[367],"Sciences,":[368],"Roche,":[369,376],"Schering-Plough":[370,378],"GlaxoSmithKline,":[371],"Merck":[372],"Sharp":[373],"&":[374],"Dohme,":[375],"sanofi-aventis,":[377]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-10-07T00:00:00"}